Rise Health & Wellness Peptides

Tirzepatide (30mg)
$310.00 USD
Buy Now
Rise Health

GLP- 1 It is the first dual GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) receptor agonist being studied for enhance glycemic control and induce significant weight loss. Its dual action makes it more effective than traditional GLP-1 therapies in both metabolic and cardiovascular health domains.

Current Research Focus ▼

Primary Research Areas:

  • Type 2 diabetes mellitus (T2DM) management
  • Chronic weight management in obesity or overweight individuals with comorbidities
  • Prediabetes intervention and diabetes prevention
  • Cardiometabolic support in heart failure with preserved ejection fraction (HFpEF)
Mechanism of Action ▼

1. GLP-1 Receptor Agonism: Enhances glucose-dependent insulin secretion, reduces glucagon release, delays gastric emptying, and supports appetite regulation.

2. GIP Receptor Agonism: Improves insulin sensitivity and complements GLP-1 signaling to enhance glycemic control and metabolic efficiency.

3. Dual Incretin Effect: Combines GLP-1 and GIP pathways to synergistically improve blood glucose regulation, promote weight reduction, and optimize lipid metabolism.

Key Research Studies ▼

1. Weight Loss Efficacy – SURMOUNT-1

  • Study focus: Long-term weight reduction in obesity and prediabetes
  • Key findings: Up to ~22% average body weight reduction over 72 weeks
  • Reported by: Reuters (clinical trial coverage)

2. Weight Loss After Lifestyle Intervention – SURMOUNT-3

  • Study focus: Weight reduction following intensive lifestyle modification
  • Key findings: Mean weight loss exceeding 20% at 72–84 weeks
  • Source: Eli Lilly Investor Report

3. Head-to-Head Comparison with Semaglutide

  • Study focus: Direct comparison of weight reduction efficacy
  • Key findings: Greater mean weight reduction compared to semaglutide
  • Source: Eli Lilly Investor Report

4. Diabetes Prevention

  • Study focus: Progression from prediabetes to type 2 diabetes
  • Key findings: Significant reduction in progression rates over multi-year follow-up
  • Source: Media clinical coverage

5. Cardiovascular Outcomes (HFpEF)

  • Study focus: Heart failure with preserved ejection fraction
  • Key findings: Reduced heart failure–related outcomes and meaningful weight reduction
  • Source: Health news coverage

6. Glycemic Control Superiority

  • Study focus: HbA1c reduction versus semaglutide
  • Key findings: Demonstrated noninferiority and superiority in HbA1c reduction over 40 weeks
  • Published in: New England Journal of Medicine
  • Link: View Study
Biological Effects and Benefits
✓
GLP-1 Receptor Agonism:
Enhances insulin response to glucose while influencing lipid metabolism and adipose tissue regulation.
✓
No Impact on Blood Sugar:
Does not directly alter baseline insulin levels or disrupt normal glucose metabolism.
Biological Effects
✓
Dual Incretin Effect:
Combines GLP-1 and GIP signaling pathways to synergistically improve glycemic control and support weight management.

Biological Effects and Benefits

Sequence (39–amino-acid synthetic peptide): Tyr–Aib–Glu–Gly–Thr–Phe–Thr–Ser–Asp–Tyr–Ser–Ile–Aib–Leu–Asp–Lys–Val–Gln–Ala–Ala–Lys–Ala–Phe–Gly–Glu–Ala–Leu–Ala–Glu–Glu–Glu–Glu–Glu–Glu–Glu–Glu–Gly–Gly–Gly

Molecular Formula: C₂₂₅H₃₄₈N₄₈O₆₈

Molecular Weight: ≈ 4,813.5 g/mol

Related Products

TB-500 (10mg)

$99.00

Buy Now

BPC-157 (15mg)

$110.00

Buy Now

NAD + (1000mg)

$145.00

Buy Now

ARA 290 (16mg)

$99.00

Buy Now